Late decisions about treatment limitation in patients with cancer : empirical analysis of end-of-life practices in a haematology and oncology unit at a German university hospital

Article indépendant

MEHLIS, Katja | BIERWIRTH, Elena | LARYIONAVA, Katsiaryna | MUMM, Friederike | HEUSSNER, Pia | WINKLER, Eva C.

Background: Decisions to limit treatment (DLTs) are important to protect patients from overtreatment but constitute one of the most ethically challenging situations in oncology practice. In the Ethics Policy for Advance Care Planning and Limiting Treatment study (EPAL), we examined how often DLT preceded a patient’s death and how early they were determined before (T1) and after (T2) the implementation of an intrainstitutional ethics policy on DLT. Methods: This prospective quantitative study recruited 1.134 patients with haematological/oncological neoplasia in a period of 2×6 months at the University Hospital of Munich, Germany. Information on admissions, discharges, diagnosis, age, DLT, date and place of death, and time span between the initial determination of a DLT and the death of a patient was recorded using a standardised form. Results: Overall, for 21% (n=236) of the 1.134 patients, a DLT was made. After implementation of the policy, the proportion decreased (26% T1/16% T2). However, the decisions were more comprehensive, including more often the combination of ‘Do not resuscitate’ and ‘no intense care unit’ (44% T1/64% T2). The median time between the determination of a DLT and the patient’s death was similarly short with 6 days at a regular ward (each T1/T2) and 10.5/9 (T1/T2) days at a palliative care unit. For patients with solid tumours, the DLTs were made earlier at both regular and palliative care units than for the deceased with haematological neoplasia. Conclusion: Our results show that an ethics policy on DLT could sensitise for treatment limitations in terms of frequency and extension but had no significant impact on timing of DLT. Since patients with haematological malignancies tend to undergo intensive therapy more often during their last days than patients with solid tumours, special attention needs to be paid to this group. To support timely discussions, we recommend the concept of advance care planning.

http://dx.doi.org/10.1136/esmoopen-2020-000950

Voir la revue «ESMO open, 5»

Autres numéros de la revue «ESMO open»

Consulter en ligne

Suggestions

Du même auteur

Late decisions about treatment limitation in ...

Article indépendant | MEHLIS, Katja | ESMO open | n°5 | vol.5

Background: Decisions to limit treatment (DLTs) are important to protect patients from overtreatment but constitute one of the most ethically challenging situations in oncology practice. In the Ethics Policy for Advance Care Plann...

Development and evaluation of an ethical guid...

Article indépendant | LARYIONAVA, Katsiaryna | JMIR research protocols | n°6 | vol.7

BACKGROUND: Many patients with advanced cancer receive chemotherapy close to death and are referred too late to palliative or hospice care, and therefore die under therapy or in intensive care units. Oncologists still have difficu...

High prevalence of moral distress reported by...

Article indépendant | MEHLIS, Katja | Psycho-oncology

OBJECTIVE: Decisions to limit life-prolonging treatment (DLT) are often accompanied by psychological and ethical difficulties. The aim of the study is to investigate prevalence and intensity of moral distress (MD) as well as poten...

De la même série

Globalization of clinical trials in oncology ...

Article indépendant | IZARN, F. | ESMO open | n°1 | vol.10

BACKGROUND: Over the past two decades, the globalization of oncology clinical trials has expanded, yet significant disparities persist across countries. This study aimed to evaluate these geographical inequalities, the evolution o...

A taxonomy of the factors contributing to the...

Article indépendant | CHERNY, N. I. | ESMO open | n°1 | vol.10

Many patients with cancer approaching the end of life (EOL) continue to receive treatments that are unlikely to provide meaningful clinical benefit, potentially causing more harm than good. This is called overtreatment at the EOL....

Health networking on cancer in the European U...

Article indépendant | CASALI, P. G. | ESMO open | n°2 | vol.10

Health networking is in principle a formidable instrument to address many challenges posed by cancer, one of the two most common and most lethal non-communicable chronic diseases. The European Union (EU)'s Beating Cancer Plan fore...

Quality-of-care indicators for oncology manag...

Article indépendant | KANESVARAN, R. | ESMO open | n°3 | vol.10

Cancer is a major cause of morbidity and mortality, with variable outcomes seen in the Asia-Pacific region due to substantial differences in cancer care and management. Quality indicators are evidence-based, standardized measures ...

Practical cancer nutrition, from guidelines t...

Article indépendant | HUSTAD, K. S. | ESMO open | n°4 | vol.10

BACKGROUND: Malnutrition affects 20%-70% of cancer patients, depending on tumour type, disease stage, and clinical setting. While nutritional care is essential for improving patients' quality of life and clinical outcomes, it is n...

Chargement des enrichissements...